

**Idiopathic Choroidal Neovascularization: Intraocular Inflammatory Cytokines
and the Effect of Intravitreal Ranibizumab Treatment**

Houfa Yin, Xiaoyun Fang*, Jian Ma, Min Chen, Yabo Yang, Shenchao Guo, Zhiqing
Chen, Zhaoan Su, Lei Feng, Panpan Ye, Fang Wu & Jinfu Yin

Eye Center, Second Affiliated Hospital of Zhejiang University School of Medicine,
Hangzhou, China. Correspondence and requests for materials should be addressed to
X.F.(email: xiaoyunfang@zju.edu.cn)

	Subgroup A (n=15)	Subgroup B (n=24)	P value
Sex, n (%)			0.317
Male	4 (26.7)	11 (45.8)	
Female	11 (73.3)	13 (54.2)	
Mean age of patients, yrs	32.1±7.4	36.9±7.7	0.062
Mean axial length, mm	24.34±1.14	24.09±1.18	0.512
Mean duration before IVR, d	52.6±59.6	59.2±55.2	0.442
Mean spherical equivalent, D	2.93±1.83	2.10±1.87	0.144
Location of CNV (subfoveal/juxtafoveal/extrafoveal), n	8/4/3	11/6/7	0.807
BCVA, logMAR			
Baseline	0.75±0.53	0.63±0.39	0.582
Month 1	0.23±0.31	0.27±0.26	0.332
Month 12	0.17±0.26	0.15±0.17	0.820
CRT, um			
Baseline	335.87±93.89	365.42±81.56	0.306
Month 1	233.87±26.95	239.38±32.19	0.795
Month 12	215.27±19.46	221.58±19.90	0.322
Lesion area, mm²			
Baseline	2.63±1.98	2.31±1.62	0.646

Supplementary Table S1. Clinical characteristics of subgroup A and subgroup B. Subgroup A, patients who received 1 injection during the 12-month follow-up period. Subgroup B, patients who received 2 or more injections during the 12-month follow-up period. Data are presented as mean ±SD or n (%).